| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $699.6M | +3.8% |
| Cost of Revenue | $433.4M | -9.3% |
| Gross Profit | $266.2M | +35.9% |
| R&D Expense | $85.7M | +5.7% |
| SG&A Expense | $78.9M | +24.3% |
| Operating Income | -$34.2M | -379.6% |
| Pre-tax Income | -$16.8M | -167.4% |
| Income Tax | $1.1M | -90.8% |
| Net Income | -$17.9M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $209.9M | -26.7% |
| Short-term Investments | $113.1M | -7.5% |
| Accounts Receivable | $142.0M | -9.1% |
| Inventory | $176.5M | +8.6% |
| Current Assets | $673.3M | -11.2% |
| Total Assets | $836.3M | -1.6% |
| Current Liabilities | $250.2M | -7.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.6M | -99.0% |
| Capital Expenditures | $20.5M | +128.1% |
| Investing Cash Flow | -$22.6M | +13.4% |
| Financing Cash Flow | -$55.5M | -92.0% |
| Free Cash Flow | -$18.9M | -112.1% |
| -245.0% |
| EPS (Basic) | -$0.63 | -246.5% |
| EPS (Diluted) | -$0.63 | -250.0% |
| Total Liabilities |
| $338.4M |
| +9.5% |
| Stockholders' Equity | $497.8M | -8.0% |